Skip to main content
CG Oncology, Inc. logo

CG Oncology, Inc. — Investor Relations & Filings

Ticker · CGON ISIN · US1569441009 US Manufacturing
Open in API
Filings indexed 173 across all filing types
Latest filing 2024-01-05 Regulatory Filings
Country US United States of America
Listing US CGON

About CG Oncology, Inc.

https://www.cgoncology.com/

CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing bladder-sparing therapeutics for patients with urologic cancers, particularly non-muscle invasive bladder cancer (NMIBC). The company's lead product candidate is cretostimogene grenadenorepvec, an investigational, intravesically delivered oncolytic immunotherapy. This therapy is designed with a dual mechanism of action to selectively replicate within and destroy cancer cells while stimulating a systemic anti-tumor immune response. The primary goal is to provide an effective treatment that preserves the bladder and improves the quality of life for patients.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2024
Regulatory Filings Classification · 95% confidence The document is a detailed letter from CG Oncology, Inc. to the U.S. Securities and Exchange Commission regarding a Registration Statement on Form S-1 for an initial public offering (IPO). It includes extensive discussion of stock option grants, valuation methodologies for common stock, and estimated fair values over multiple dates. The content is focused on the IPO process, stock valuation, and related financial disclosures. The document is not an annual or quarterly report, audit report, earnings release, or any other typical financial report. It is a regulatory filing submitted to the SEC as part of the IPO registration process, specifically a Form S-1 registration statement correspondence. The document is lengthy (15,000 characters) and contains substantive financial and valuation information, but it is not a report like a 10-K or IR. It is a regulatory filing related to the IPO registration process. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2024-01-05 English
Regulatory Filings 2024
Regulatory Filings Classification · 100% confidence The document is a letter from the company's legal counsel responding to comments from the SEC staff regarding a Draft Registration Statement on Form S-1. It discusses amendments and revisions to the Registration Statement, including financial data, management disclosures, and regulatory designations. The document is not the Registration Statement itself but a correspondence related to the registration process. It is a regulatory communication addressing SEC comments on a draft filing, not a financial report, earnings release, or other specific report type. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory communications that do not fit other categories.
2024-01-02 English
S-1
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, dated January 2, 2024, for CG Oncology, Inc. It is a detailed registration statement under the Securities Act of 1933, used for initial public offerings (IPOs). The text includes extensive information typical of an S-1 filing: company overview, risk factors, management discussion, financial data, use of proceeds, underwriting details, and legal matters. This is not an annual report, earnings release, or any other report type but a registration statement for securities offering. The S-1 is a capital markets filing related to fundraising and securities registration, which aligns with the Capital/Financing Update (CAP) category in the classification scheme. Therefore, the document should be classified as a Capital/Financing Update (CAP). The document length (15,000 characters) and content confirm it is the full registration statement, not just an announcement or summary.
2024-01-02 English
Regulatory Filings 2023
Regulatory Filings
2023-12-18 English
Regulatory Filings 2023
Regulatory Filings Classification · 100% confidence The document is a detailed response letter from a law firm to the SEC staff regarding comments on a confidential draft Registration Statement on Form S-1 for CG Oncology, Inc. It addresses SEC staff comments on the draft Registration Statement, including prospectus summary, clinical trial disclosures, management discussion and analysis, accounting policies, and other regulatory compliance matters. The document references the draft Registration Statement and its amendments but does not itself contain financial statements or the full registration statement. It is a regulatory correspondence related to the registration process, not the registration statement itself or a financial report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory correspondence and filings that do not fit other categories.
2023-12-04 English
Capital/Financing Update 2023
Capital/Financing Update Classification · 95% confidence The document is a Form S-1 Registration Statement filed with the SEC, which is used for initial public offerings (IPOs) to register securities under the Securities Act of 1933. It contains detailed information about the company, its business, risk factors, management, financial data, and the offering itself. This is not an annual report, earnings release, or any other type of financial report but a registration statement for capital raising and public listing. Therefore, it fits best under the category of Capital/Financing Update (CAP), which includes updates on company fundraising and financing activities such as IPOs.
2023-12-04 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.